Koren MJ, Sabatine MS, Giugliano RP, et al. - Given a reduction in adverse cardiovascular outcomes, induced by evolocumab and other anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies, has been reported in clinical trials of high-risk patients over < 3 years median treatment duration, researchers focused on the longer-term influences of evolocumab during open-label hypercholesterolemia treatment for up to 5 years in OSLER-1 trial (Open Label Study of Long Term Evaluation Against LDL-C Trial). The randomization of the patients to standard of care (SOC) or evolocumab 420 mg monthly (evolocumab + SOC) for year 1 was done. Following year 1, patients could enter the all-evolocumab period and treated with evolocumab + SOC for an extra 4 years. Evolocumab displayed consistently excellent low-density lipoprotein cholesterol–lowering effectiveness, tolerance, as well as safety, with no evidence of neutralizing antibodies, during this longest-duration analysis of a PCSK9 inhibitor reported to date.